Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Evolution of uncontrolled proliferation and the angiogenic switch in cancer

1. Department of Life Sciences, Scottsdale Community College, 9000 E. Chaparral Rd., Scottsdale, AZ 85256
2. School of Mathematical and Statistical Sciences, Arizona State University, PO Box 874501, Tempe AZ, 85287-1804

The major goal of evolutionary oncology is to explain how malignant traits evolve to become cancer "hallmarks." One such hallmark---the angiogenic switch---is difficult to explain for the same reason altruism is difficult to explain. An angiogenic clone is vulnerable to "cheater" lineages that shunt energy from angiogenesis to proliferation, allowing the cheater to outcompete cooperative phenotypes in the environment built by the cooperators. Here we show that cell- or clone-level selection is sufficient to explain the angiogenic switch, but not because of direct selection on angiogenesis factor secretion---angiogenic potential evolves only as a pleiotropic afterthought. We study a multiscale mathematical model that includes an energy management system in an evolving angiogenic tumor. The energy management model makes the counterintuitive prediction that ATP concentration in resting cells increases with increasing ATP hydrolysis, as seen in other theoretical and empirical studies. As a result, increasing ATP hydrolysis for angiogenesis can increase proliferative potential, which is the trait directly under selection. Intriguingly, this energy dynamic allows an evolutionary stable angiogenesis strategy, but this strategy is an evolutionary repeller, leading to runaway selection for extreme vascular hypo- or hyperplasia. The former case yields a tumor-on-a-tumor, or hypertumor, as predicted in other studies, and the latter case may explain vascular hyperplasia evident in certain tumor types.
  Figure/Table
  Supplementary
  Article Metrics

Keywords evolutionary suicide; adaptive dynamics; energy charge; multiscale models; perturbation expansion.; Cancer; ATP

Citation: John D. Nagy, Dieter Armbruster. Evolution of uncontrolled proliferation and the angiogenic switch in cancer. Mathematical Biosciences and Engineering, 2012, 9(4): 843-876. doi: 10.3934/mbe.2012.9.843

 

This article has been cited by

  • 1. R. A. Everett, J. D. Nagy, Y. Kuang, Dynamics of a Data Based Ovarian Cancer Growth and Treatment Model with Time Delay, Journal of Dynamics and Differential Equations, 2016, 28, 3-4, 1393, 10.1007/s10884-015-9498-y
  • 2. Louise Viger, Fabrice Denis, Clément Draghi, Thibault Ménard, Christophe Letellier, Spatial avascular growth of tumor in a homogeneous environment, Journal of Theoretical Biology, 2017, 416, 99, 10.1016/j.jtbi.2016.12.011
  • 3. Philip Gerlee, Alexander R A Anderson, The evolution of carrying capacity in constrained and expanding tumour cell populations, Physical Biology, 2015, 12, 5, 056001, 10.1088/1478-3975/12/5/056001
  • 4. Louise Viger, Fabrice Denis, Martin Rosalie, Christophe Letellier, A cancer model for the angiogenic switch, Journal of Theoretical Biology, 2014, 360, 21, 10.1016/j.jtbi.2014.06.020
  • 5. Javad Salimi Sartakhti, Mohammad Hossein Manshaei, David Basanta, Mehdi Sadeghi, Wen-Bo Du, Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game, PLOS ONE, 2017, 12, 4, e0175063, 10.1371/journal.pone.0175063
  • 6. Scott T. Bickel, Joseph D. Juliano, John D. Nagy, Juan F. Poyatos, Evolution of Proliferation and the Angiogenic Switch in Tumors with High Clonal Diversity, PLoS ONE, 2014, 9, 4, e91992, 10.1371/journal.pone.0091992
  • 7. Bernard Crespi, Kevin Foster, Francisco Úbeda, First principles of Hamiltonian medicine, Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 1642, 20130366, 10.1098/rstb.2013.0366
  • 8. Anni S. Halkola, Kalle Parvinen, Henna Kasanen, Satu Mustjoki, Tero Aittokallio, Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies, Journal of Theoretical Biology, 2019, 110136, 10.1016/j.jtbi.2019.110136
  • 9. Inmaculada C. Sorribes, Samuel K. Handelman, Harsh V. Jain, Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition, Journal of The Royal Society Interface, 2020, 17, 162, 20190722, 10.1098/rsif.2019.0722
  • 10. Konstantin E. Starkov, A Cancer Model for the Angiogenic Switch and Immunotherapy: Tumor Eradication in Analysis of Ultimate Dynamics, International Journal of Bifurcation and Chaos, 2020, 30, 10, 2050150, 10.1142/S0218127420501503

Reader Comments

your name: *   your email: *  

Copyright Info: 2012, , licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved